Comparing Mainz Biomed (NASDAQ:MYNZ) & DEFSEC Technologies (NASDAQ:DFSC)

Mainz Biomed (NASDAQ:MYNZ) and DEFSEC Technologies (NASDAQ:DFSC) are both small-cap industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Insider and Institutional Ownership

21.4% of DEFSEC Technologies shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Mainz Biomed and DEFSEC Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1	1	0	0	1.50
DEFSEC Technologies	1	0	0	0	1.00

Profitability

This table compares Mainz Biomed and DEFSEC Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
DEFSEC Technologies	-120.97%	-144.66%	-82.13%

Earnings and Valuation

This table compares Mainz Biomed and DEFSEC Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659,935.00	14.14	-$21.65 million	($65.60)	-0.02
DEFSEC Technologies	$3.53 million	0.42	-$6.88 million	($4.62)	-0.16

DEFSEC Technologies has higher revenue and earnings than Mainz Biomed. DEFSEC Technologies is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Mainz Biomed has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, DEFSEC Technologies has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500.

Summary

Mainz Biomed beats DEFSEC Technologies on 7 of the 12 factors compared between the two stocks.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

About DEFSEC Technologies

DEFSEC develops and commercializes breakthrough next-generation tactical systems for military and security forces. The Company’s current portfolio of offerings includes digitization of tactical forces for real-time shared situational awareness and targeting information from any source (including drones) streamed directly to users’ smart devices and weapons. Other DEFSEC products include countermeasures against threats such as electronic detection, lasers and drones. These systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems, and all come integrated with TAK. The Company also has a new proprietary non-lethal product line branded PARA OPSTM with applications across all segments of the non-lethal market, including law enforcement. The Company is headquartered in Ottawa, Canada, with representative offices in London, UK and Abu Dhabi, UAE.